Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.68 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.68 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.68 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 4/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | PRKCG | P05129 | 1/20 | 0.52 |
| ▸ | PRKCB | P05771 | 1/20 | 0.52 |
| ▸ | PRKCA | P17252 | 1/20 | 0.52 |
| ▸ | PRKCH | P24723 | 1/20 | 0.52 |
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.52 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.52 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.50 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7183039 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL30510651 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL30910033 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL30510614 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL8636551 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4204833 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL303128 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL7563995 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4879843 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4204708 | 1.00 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4705454-A2 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | Stoke Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705455-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | Stoke Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260055409-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2025-09-23 | — | — | US | disclosed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2024229421-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024227085-A2 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2024-03-14 | — | — | US | disclosed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-7608705-B2 | nucleobases are cytosine groups or mimetics; modified with polyethyleneglycol or a tocopheryl group; useful in inhibiting proliferation of pancreatic tumors | UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (DE) | 2009-10-27 | — | — | US | disclosed |
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20080199960-A1 | Methods for the Delivery of Oligomeric Compounds | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-08-21 | — | — | US | disclosed |
| WO-2006031461-A2 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20050119470-A1 | Conjugated oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050019761-A1 | Oligonucleotides, agents containing these oligonucleotides, and the use thereof | UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004044141-A2 | CONJUGATED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1326878-A2 | OLIGONUCLEOTIDES, AGENTS CONTAINING THESE OLIGONUCLEOTIDES, AND THE USE THEREOF | Bayer, Ernst, Prof. Dr. (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002026754-A9 | OLIGONUCLEOTIDES, AGENTS CONTAINING THESE OLIGONUCLEOTIDES, AND THE USE THEREOF | BAYER ERNST (DE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002026754-A2 | OLIGONUCLEOTIDES, AGENTS CONTAINING THESE OLIGONUCLEOTIDES, AND THE USE THEREOF | BAYER ERNST (DE) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | LPAR1 75/4885LPAR3 32/4885LPAR2 106/4885 |
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | PHAX, RIOX2, RNMT | LPAR1 2494/4885LPAR3 1618/4885LPAR2 1751/4885 |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | LPAR1 295/4885LPAR3 347/4885LPAR2 236/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | LPAR1 540/4885LPAR3 239/4885LPAR2 379/4885 |
| US-20260055409-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | CYFIP1, SYNGR2, CYFIP2 | LPAR1 3026/4885LPAR3 3949/4885LPAR2 3163/4885 |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | PCSK9, SCD5, PCSK7 | LPAR1 540/4885LPAR3 239/4885LPAR2 379/4885 |
| US-20050119470-A1 | Conjugated oligomeric compounds and their use in gene modulation | PHAX, SNRPE, RRP1B | LPAR1 1902/4885LPAR3 1338/4885LPAR2 1366/4885 |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | PCSK9, PCSK7, PCSK6 | LPAR1 75/4885LPAR3 32/4885LPAR2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.